Shots: Indivumed to receive upfront from Evotec, for accessing Indivumed’s database “IndivuType” and both companies will jointly invest in data analysis, target identification, validation, and drug discovery. Evotec will be responsible for upcoming partnering for the program/platform The focus of the agreement is to develop precision therapies for CRC patients with the combination of Evotec’s […]Read More
Shots: The IND submission under FDA is in response to onset P-I/II clinical trial for MRTX849, to evaluate its safety, PK & tolerability With the IND acceptance, the trial will use an accelerated titration design with single patient cohorts and intra-patient dose for MRTX849 & P-II expansion cohorts will enroll patients with +ve KRAS G12C […]Read More
Shots: • Celltrion has completed Phase I on safety and efficacy of CT-P16 in June 18 • CT-P16 extended to Phase III as planned by submission of application to National Authority of Medicines and Health Products, I.P. (Infarmed) of Portugal • Celltrion has plan to conduct Phase III clinical trial […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
